Proceedings a GOG workshop on intraperitoneal therapy ovarian cancer Gynecologic Oncology
CTEP Staff Publications 2008 Brave, M., Goodman, V., Kaminskas, E., Farrell, A., Timmer, W., Pope, S., Harapanhalli, R., Saber, H., Morse, D., Bullock, J., Men, A., Noory, C., Ramchandani, R., Kenna, L., Booth, B., Gobburu, J., Jiang, X., Sridhara, R., Justice, R., and Pazdur, R. (2008). Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clinical Cancer Research, 14(2), 352-359. Come, S., Buzdar, A., Ingle, J., Johnston, S., Brodie, A., Coombes, R., Mille, W., Pritchard, K., Winer, E., Zujewski, J., and Goss, P. (2008). Endocrine and targeted manipulation of breast cancer: summary statement from the Sixth Cambridge Conference. Cancer, 112(3 Suppl), 673-8. Eng-Wong, J., and Zujewski, J. (2008). Current NCI-sponsored cooperative trials of endocrine therapy in breast cancer. Cancer, 112(3 Suppl), 723-9. Eng-Wong, J., Orzano-Birgani, J.A., Chow, C.K., Venzon, D., Yao, J., Galbo, C.E., Zujewski, J., and Prindiville, S. (2008). The effect of raloxifene on mammographic density and breast MRI in premenopausal women at increased risk for breast cancer. Cancer Epidemiology, Biomarkers and Prevention, 7, 1696-701. Goss, P.E., Ingle J.N., Pater J.L., Martino S., Robert N.J., Muss, H.B., Piccart, M.J., Castiglione, M., Sherpherd, L.E., Pritchard, K.I., Livingston, R.B., Davidson, N.E., Norton, L., Perez, E.A., Abrams, J.S., Cameron, D.A., Palmer, M.J., and Tu, D. (2008). Late extended adjuvant treatment with letrozole improves outcome in early-stage breast cancer in women who complete 5 years of tamoxifen. Journal of Clinical Oncology, 26, 1948-1955. Gralow, J.R., Zujewski, J., and Winer, E. (2008). Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. Journal of Clinical Oncology, 26(5), 696-7. Houghton, P., Morton, C., Kolb, E., Gorlick, R., Lock, R., Carol, H., Reynolds, C., Maris, J., Keir, S., Billups, C., and Smith, M. (2008). Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatric Blood and Cancer, 50(4), 799-805. Houghton, P., Morton, C., Kolb, E., Lock, R, Carol,. H., Reynolds, C., Keshelava, N., Maris, J., Keir, S., Wu, J., and Smith, M. (2008). Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 50(1), 37-45. Hunsberger, S., Freidlin, B., and Smith, M. (2008). Complexities in interpretation of osteosarcoma clinical trial results. Journal of Clinical Oncology, 26(18), 3103-3104. Ingle, J.N., Tu, D., Pater, J.L., Muss, H.B., Martino, S., Robert, N.J., Piccart, M.G., Castiglione, M., Shepherd, L.E., Pritchard, K.I., Livingston, R.B., Davidson, N.E., Norton, L., Perez, E.A., Abrams, J.S., Cameron, D.A., Palmar, M.J., and Goss, P.E. (2008). Intent to treat analysis of the placebo-controlled trial of Letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Annals of Oncology, 19, 872-882. Keir, S., Morton, C., Billups, C., Smith, M., Houghton, P., and Gururangan, S. (2008). Initial testing of VNP40101M (Cloretazine) by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 51(3), 439-44. Kolb, E., Gorlick, R., Houghton, P., Morton, C., Lock, R., Carol, H., Reynolds, C., Maris, J., Keir, S., Billups, C., and Smith, M. (2008). Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatric Blood and Cancer, 50(6), 1190-1197. Kolb, E., Gorlick, R., Houghton, P., Morton, C., Lock, R., Tajbakhsh, M., Reynolds, C., Maris, J., Keir, S., Billups, C., and Smith, M. (2008). Initial testing of dasatinib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 50(6), 1198-1206. Little, R., Denicoff, A., and Trimble, E. (2008). Reversible features of cervical cancer in human immunodeficiency virus infection: impaired access, impaired surveillance, impaired immunity, impaired outcomes (editorial). Cancer, 112(12), 2627-30. Lock, R., Carol, H., Houghton, P., Morton, C., Kolb, E., Gorlick, R., Reynolds, C., Maris, J., Keir, S., Wu, J., and Smith, M. (2008). Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 50(6), 1181-1189. Website: http://www.ncbi.nlm.nih.gov/pubmed/18085673 Maris, J., Courtright, J., Houghton, P., Morton C., Gorlick, R., Kolb, E., Lock, R., Tajbakhsh, M., Reynolds, C., Keir, S., Wu, J., and Smith, M. (2008). Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 50, 581-587. Maris, J., Courtright, J., Houghton, P., Morton, C., Kolb, E., Lock, R., Tajbakhsh, M., Reynolds, C., Keir. S., Wu, J., and Smith, M. (2008). Initial testing (stage 1) of sunitinib by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 51(1), 42-48. Website: http://www.ncbi.nlm.nih.gov/pubmed/18293383 Murgo, A.J., Kummar, S., Rubinstein, L., Gutierrez, M., Collins, J., Kinders, R., Parchment, R.E., Ji, J., Steinberg, S.M., Yang, S.X., Hollingshead, M., Chen, A., Helman, L., Wiltrout, R., Tomaszewski, J.E. and Doroshow, J.H. (2008). Designing Phase 0 Cancer Clinical Trials. Clinical Cancer Research, 14, 3675-3682. Neale, G., Su, X., Morton, C., Phelps, D., Gorlick, R., Lock, R., Reynolds, C., Maris, J., Friedman, H., Dome, J., Khoury, J., Triche, T., Seeger, R., Gilbertson. R., Khan, J., Smith, M., and Houghton, P. (2008). Molecular characterization of the Pediatric Preclinical Testing Panel. Clinical Cancer Research, 14(14), 4572-4583. Smith, M., Morton, C., Phelps, D., Girtman, K., Neale, G., and Houghton, P. (2008). SK- NEP-1 and Rh1 are Ewing family tumor lines. Pediatric Blood and Cancer, 50(3), 703-706. Website: http://www.ncbi.nlm.nih.gov/sites/entrez?db=PubMed&cmd=retrieve&dopt=AbstractPlus&list_uids=17154184 Smith, M., Morton, C., Phelps, D., et al. (2008). Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 51(1), 34-41. Stroup, A., Harlan, L., and Trimble, E. (2008). Demographic, clinical and treatment trends among women diagnosed with vulvar cancer in the United States. Gynecologic Oncology, 108(3), 577-83. Tajbakhsh, M., Houghton, P., Morton, C., Kolb, E., Gorlick, R., Maris, J., Keir, S., Wu, J., Reynolds, C., Smith, M., and Lock, R. (2008). Initial testing of cisplatin by the pediatric preclinical testing program. Pediatric Blood and Cancer, 50(5), 992-1000. Trimble, E., Harlan, L., Gius, D., Stevens, J., and Schwartz, S. (2008). Patterns of care for women with cervical cancer in the United States. Cancer, 113(4), 743-9. Wolff, A.C., Berry, D., Carey, L.A., Colleoni, M., Dowsett, M., Ellis, M., Garber, J.E., Mankoff, D., Paik, S., Pusztai, L., Smith, M.L., and Zujewski, J. (2008). Research issues affecting pre-operative systemic therapy for operable breast cancer. Journal of Clinical Oncology, 26(5), 806-13. 2007 Whiteford, C., Bilke, S., Greer, B., et al. (2007). Credentialing Preclinical Pediatric Xenograft Models Using Gene Expression and Tissue Microarray Analysis. Cancer Research, 67(1), 32-40. Aragon-Ching, J. and Zujewski, J. (2007). CNS Metastasis: An old problem in a new guise. Clinical Cancer Research, 13(6), 1644-1647. Hudis, C., Barlow W., Costantino, J., Gray R., Pritchard K., Chapman J., Sparano J., Hunsberger, S., Enos R., Gelber R., and Zujewski, J. (2007). Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. Journal of Clinical Oncology, 25(15), 2127-32. Freidlin, F., Korn, E. L., Hunsberger, S., Gray, R., Saxman, S., and Zujewski, J. (2007). Progression-Free Survival in Unblinded Randomized Trials. Journal of Clinical Oncology, 25, 2122-2126. Trimble, E., Davis, J., DiSaia, P., et al. (2007). Clinical trials in gynecological cancer. International Journal of Gynecological Cancer, 17(3), 547-56. Gaffney, D., Du Bois, A., Narayan, K., Reed, N., Toita, T., Pignata, S., Blake, P., Portelance, L., Sadoyze, A., Pötter, R., Colombo, A., Randall, M., Mirza, M., and Trimble, E. (2007). Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG). International Journal of Radiation Oncology Biology, Physics, 68(2), 485-90. Rapkiewicz, A., Espina V., Zujewski, J., Lebowitz, P.F., Filie, A., Wulfkuhle, J., Camphausen, K., Petricoin E.F., Liotta, L., and Abati, A. (2007). The needle in the haystack: Application of breast Fine Needle Aspirate samples to quantitative protein microarray technology. Cancer (Cancer Cytopathology), 111, 173-84. Kummar, S., Gutierrez, M., Gardner, E., Donovan, E., Hwang, K., Chung, E., Lee, M., Maynard, K., Kalnitskiy, M., Chen, A., Melillo, G., Ryan, Q., Conley, B., Figg, W., Trepel, J., Zwiebel, J., Doroshow J., and Murgo, A. (2007). Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies. Clinical Cancer Research, 13, 5411-5417. Rubinstein, L., Dancey, J., Korn, E., et al. (2007). Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise? Journal of the National Cancer Institute, 99(19), 1422-1423. Minasian, L., O’Mara, A., Reeve, B., Denicoff, A., Kelaghan, J., Rowland, J., and Trimble, E. (2007). Health-related quality of life and symptom management research sponsored by the National Cancer Institute. Journal of Clinical Oncology, 25(32) 5128-32. Website: http://www.ncbi.nlm.nih.gov/pubmed/17991932 Lipscomb, J., Reeve, B., Clauser, S., Abrams, J., Watkins-Bruner, D., Burke, L.B., Denicoff, A., Ganz, P., Gondek, K., Minasian, L., O'Mara, A., Revicki, D.A., Rock, E., Rowland, J., Sgambati, M., and Trimble, E. (2007). Patient-Reported Outcomes Assessment in Cancer Trials: Taking Stock, Moving Forward. Journal of Clinical Oncology, 25, 5133-40. Clauser, S., Ganz, P., Lipscomb, J., and Reeve, B. (2007). Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. Journal of Clinical Oncology, 25(32), 5133-40. Farley, J., Harlan, L., Clegg, L., Larsen, W., and Trimble, E. (2007). Patterns of care for cervical cancer patients treated in the U.S. military health care system. Journal of Reproductive Medicine, 52(11), 1040-5. Premkumar, A., Venzon, D.J., Avila, N., Johnson, D.V., Remaley, A.T., Forman, M.R., Eng-Wong, J., Zujewski, J., and Stratton, P. (2007). Gynecologic and hormonal effects of raloxifene in pre-menopausal subjects at high risk for developing breast cancer. Fertility and Sterility, 88(6),1637-44. Houghton, P., Morton, C., Tucker, C., et al. (2007). The Pediatric Preclinical Testing Program: description of models and early testing results. Pediatric Blood and Cancer, 49(7), 928-940. Kinders, R., Parchment, R., Ji, J., Kummar, S., Murgo, A., Gutierrez, M., Collins, J., Rubinstein, L., Pickeral, O., Steinberg, S., Yang, S., Hollingshead, M., Chen, A., Helman, L., Wiltrout, R., Simpson, M., Tomaszewski, J., and Doroshow, J. (2007). Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice. Molecular Interventions, 7, 325-334. 2006 Mariotto, A., Feuer, E., Harlan, L., and Abrams, J. (2006). Dissemination of Adjuvant Multiagent Chemotherapy and Tamoxifen for Breast Cancer in the U.S. using Estrogen Receptor Information: 1975-1999. Journal of the National Cancer Institute Monographs, 36, 7-15. Website: http://www.ncbi.nlm.nih.gov/pubmed/17032888 Trimble, E. and Christian, M. (2006). Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecologic Oncology,100(1), 3-4. Wedam, S., Low, J. A., Yang, S. X., Chow, C. K., Chyke, P., Danforth, D., Hewitt, S. M., Berman, A., Steinberg, S., Liewehr, D.L., Plehn, J., Doshi, A., Thomasson, D., McCarthy, N., Koeppen, H., Sherman, M., Zujewski, J., Camphausen, K., Chen, H., and Swain, S.M. (2006). Anti-angiogenic and anti-tumor effects of bevacizumab in inflammatory and locally advanced breast cancer patients. Journal of Clinical Oncology, 24(5), 769-777. Website: http://www.ncbi.nlm.nih.gov/pubmed/16391297 Harlan, L., Clegg, L., Abrams, J., Stevens, J., and Ballard-Barbash, R. (2006). Community Based Use of Chemotherapy and Hormonal Therapy for Early Stage Breast Cancer: 1987-2000. Journal of Clinical Oncology, 24(6), 872-7. Website: http://www.ncbi.nlm.nih.gov/pubmed/16484696 Trimble E. and Christian M. (2006). Cancer treatment and the older patient. Clinical Cancer Research, 12 (7 Pt 1), 1956-7. Disis, M., Rivkin, S., Baron, A., Markman, M., Connolly, D., Ueland, F., Kohn, E., Trimble, E., and Berek, J. (2006). Progress in ovarian cancer research: proceedings of the 5th Biennial Ovarian Cancer Research Symposium. International Journal of Gynecological Cancer, 16(2), 463-9. Website: http://www.ncbi.nlm.nih.gov/pubmed/16681712 Smith, Malcolm. (2006). Double trouble: cancer in twins. Pediatric Blood and Cancer, 46(4), 412-413. Faupel-Badger, J., Prindiville, S., Venzon, D., Vonderhaar, B., Zujewski, J., and Eng-Wong, J. (2006). Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Cancer Epidemiology, Biomarkers & Prevention, 15(6), 1-6. Zujewski, J., Enos, M.A., and Mason, S. (2006). Clinical trials referral resource. Current phase III breast cancer clinical trials. Oncology (Williston Park, N.Y.). 20(7), 696, 700, 702. Website: http://www.ncbi.nlm.nih.gov/pubmed/16841794 Chen, H.X., Mooney, M., Boron, M., Vena, D., Mosby, K., Grochow, L., Jaffe, C., Rubinstein, L., Zwiebel, J., and Kaplan, R.S. (2006). Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. Journal of Clinical Oncology, 21, 3354-60. Website: http://www.ncbi.nlm.nih.gov/pubmed/16849749 Eng-Wong J, Reynolds JC, Venzon D, Liewehr D, Gantz S, Danforth D, Liu ET, Chow C, and Zujewski, J. (2006). Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. Journal of Clinical Endocrinology and Metabolism. 91(10), 3941-3946. Fountain, J., Trimble, E., and Birrer, M. (2006). The 2005 Ovarian Cancer State of the Science Meeting Summary and discussion of session recommendations. Gynecologic Oncology,103 (2 Suppl 1): S23-5. Trimble, E. and Alvarez, R. (2006). Intraperitoneal chemotherapy and the NCI clinical announcement. Gynecologic Oncology, 103 (2 Suppl 1):S18-9. Chatterton, R. Zujewski, J., Mateo, E.T., Eng-Wong, J., and Jordan, V.C. (2006). Effect of Raloxifene on Salivary Sex Steroid Concentrations in premenopausal Women. Journal of Endocrinology. 191(3), 599-604. Alberts, D., Markman. M., Muggia, F., Ozols, R., Eldermire, E., Bookman, M., Chen, T., Curtin, J., Hess, L., Liebes, L., Young, R., and Trimble, E. (2006). Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. Gynecologic Oncology, 103(3), 783-92. Hazarika, M., Jiang, X., Liu, Q., Lee, S.L., Ramchandani,R., Garnett, C., Orr, M.S., Sridhara, R., Booth, B., Leighton, J.K., Timmer, W., Harapanhalli, R., Dagher, R., Justice, R., and Pazdur, R. (2008).Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib. Clinical Cancer Research, 14(9), 5325-5331. |
See all the reviews